Literature DB >> 12494183

[NOS3 gene polymorphism and left ventricular hypertrophy in patients with essential hypertension].

L O Minushkina, D A Zateĭshchikov, A A Zateĭshchikova, I V Zotova, O Yu Kudriashova, V V Nosikov, B A Sidorenko.   

Abstract

One hundred nine patients with essential hypertension were studied (50 male and 59 female, mean age - 62,6-/+1,08 years). Seventy six patients had left ventricular hypertrophy measured by echocardiography. NOS3 polymorphisms (Glu298Asp and ecNOS4a/4b) were studied by PCR. In patients without left ventricular hypertrophy (LVH) genotypes frequencies of NOS3 (Glu298Asp) were: Glu/Glu - 34.4%; Glu/Asp - 62,5%; Asp/Asp - 3,1%. In patients with LVH - Glu/Glu - 55.3%; Glu/Asp - 40.8%; Asp/Asp - 3.9%; p=0,117. Percent of Glu/Glu genotype was significantly higher in LVH group (p=0,047). Genotypes frequencies of ecNOS4a/4b were: in patients without LVH - 4b/4b - 37,5%; 4a/4b - 62,5%; 4a/4a - 0; in patients with LVH - 4b/4b - 21.1%; 4a/4b - 76.3%; 4a/4a - 2,6%;. p=0,151. Patients with 4a allele had higher Amax than 4b/4b patients (76,3+2,11 m/s and 67,9+4,72 m/s; p=0,040). Therefore, we show associations between Glu allele of NOS3 (Glu298Asp) and left ventricular hypertrophy and between 4a allele (ecNOS4a/4b) and diastolic dysfunction in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12494183

Source DB:  PubMed          Journal:  Kardiologiia        ISSN: 0022-9040            Impact factor:   0.395


  2 in total

1.  Bioinformatic identification and characterization of human endothelial cell-restricted genes.

Authors:  Manoj Bhasin; Lei Yuan; Derin B Keskin; Hasan H Otu; Towia A Libermann; Peter Oettgen
Journal:  BMC Genomics       Date:  2010-05-28       Impact factor: 3.969

2.  Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study.

Authors:  Ignacio Cruz-González; Esther Corral; María Sánchez-Ledesma; Angel Sánchez-Rodríguez; Cándido Martín-Luengo; Rogelio González-Sarmiento
Journal:  BMC Cardiovasc Disord       Date:  2009-08-04       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.